secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001816590-25-000103
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Pathways reports Q2 2025 net loss $38.4M; COMP360 Phase 3 trial hits primary endpoint
--------------------------------------------------------------------------------

- Positive Phase 3 COMP005 trial: primary endpoint met with high statistical significance and clinically meaningful reduction in depression symptoms at 6 weeks for COMP360 in TRD.
- Second pivotal Phase 3 (COMP006) enrolling well; 26-week data expected H2 2026.
- Exploring accelerated filing pathway for COMP360 in TRD; DSMB found no safety concerns in Phase 3 studies.
- Net loss $38.4M (Q2 2025) vs $38.1M (Q2 2024); net loss per share $0.41 vs $0.56.
- Cash $221.9M at June 30, 2025; cash runway into 2027; FY2025 net cash used in ops guidance $120-145M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000181659025000103/0001816590-25-000103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000181659025000103/cmps-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001816590-25-000103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer